Oncology Drugs Market Global Report 2017
出 版 商：TBRC
出版日期：2017/07/17
頁 數：125頁
文件格式：PDF
價 格：
USD 4,000 (Single-User License)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
Oncology Drugs market covers drugs that are used in the treatment of a wide range of cancer, sarcoma, and tumor. Some of the bestselling oncology drugs in 2016 include Avastin, Herceptin, Revlimid, MabThera/Rituxan, Gleevac/Glivec, Alimta, Zytiga, Tasigna, Sandostatin, and Afinitor.
The global oncology drugs market was estimated to be around $118 billion as of 2016. The oncology drugs market market made up around 11% of the overall pharmaceuticals market in 2016. The oncology drugs market was the fifth largest market in the global pharmaceutical market in 2016.
R&D Activities
Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.
The global oncology drugs market was estimated to be around $118 billion as of 2016. The oncology drugs market market made up around 11% of the overall pharmaceuticals market in 2016. The oncology drugs market was the fifth largest market in the global pharmaceutical market in 2016.
R&D Activities
Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.
1. Oncology Drugs Market Characteristics;
2. Oncology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Oncology Drugs Market Customer Information;
5. Oncology Drugs Market Segmentation;
5.1. Global Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 5.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Oncology Drugs Market Trends And Strategies;
6. Oncology Drugs Market Regional And Country Analysis;
6.1. Global Oncology Drugs Market, 2016, By Region; 6.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Oncology Drugs Market, 2016, By Country; 6.4. Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Oncology Drugs Market Comparison With Macro Economic Factors;
7.1. Oncology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Oncology Drugs Expenditure, Global;
8. Oncology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Oncology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Oncology Drugs Expenditure, By Country;
9. Oncology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Cancer, 2016, By Country;
10. Asia-Pacific Oncology Drugs Market;
10.1.1. Asia-Pacific Oncology Drugs Market Overview; 10.1.2. Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.2. Asia-Pacific Oncology Drugs Market: Country Analysis; 10.3. China Oncology Drugs Market; 10.3.1. China Oncology Drugs Market Overview; 10.3.2. China Oncology Drugs Historic Market, 2012 - 2016; 10.3.3. China Oncology Drugs Forecast Market, 2016 - 2020; 10.3.4. China Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.3.5. China Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.4. India Oncology Drugs Market; 10.4.1. India Oncology Drugs Market Overview; 10.4.2. India Oncology Drugs Historic Market, 2012 - 2016; 10.4.3. India Oncology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.4.5. India Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.5. Japan Oncology Drugs Market; 10.5.1. Japan Oncology Drugs Market Overview; 10.5.2. Japan Oncology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Oncology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.6. Australia Oncology Drugs Market; 10.6.1. Australia Oncology Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Oncology Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.6.4. Australia Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
11. Western Europe Oncology Drugs Market;
11.1.1. Western Europe Oncology Drugs Market Overview; 11.1.2. Western Europe Oncology Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Oncology Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.2. Western Europe Oncology Drugs Market: Country Analysis; 11.3. UK Oncology Drugs Market; 11.3.1. UK Oncology Drugs Market Overview; 11.3.2. UK Oncology Drugs Historic Market, 2012 - 2016; 11.3.3. UK Oncology Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.3.5. UK Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.4. Germany Oncology Drugs Market; 11.4.1. Germany Oncology Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Oncology Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.5 France Oncology Drugs Market; 11.5.1 France Oncology Drugs Historic Market, 2012 - 2016; 11.5.2 France Oncology Drugs Forecast Market, 2016 - 2020; 11.5.3 France Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.5.4 France Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.6. Italy Oncology Drugs Market; 11.6.2. Italy Oncology Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.6.4. Italy Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.7. Spain Oncology Drugs Market; 11.7.1. Spain Oncology Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Oncology Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.7.4. Spain Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Oncology Drugs Market;
12.1.1. Eastern Europe Oncology Drugs Market Overview; 12.1.2. Eastern Europe Oncology Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Oncology Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.2. Eastern Europe Oncology Drugs Market: Country Analysis; 12.3. Russia Oncology Drugs Market; 12.3.1. Russia Oncology Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Oncology Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.3.4. Russia Oncology Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
13. North America Oncology Drugs Market;
13.1.1. North America Oncology Drugs Market Overview; 13.1.2. North America Oncology Drugs Historic Market, 2012 - 2016; 13.1.3. North America Oncology Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.2. North America Oncology Drugs Market: Country Analysis; 13.3. USA Oncology Drugs Market; 13.3.1. USA Oncology Drugs Historic Market, 2012 - 2016; 13.3.2. USA Oncology Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.3.4. USA Oncology Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
14. South America Oncology Drugs Market;
14.1.1. South America Oncology Drugs Market Overview; 14.1.2. South America Oncology Drugs Historic Market, 2012 - 2016; 14.1.3. South America Oncology Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.2. South America Oncology Drugs Market: Country Analysis; 14.3. Brazil Oncology Drugs Market; 14.3.1. Brazil Oncology Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Oncology Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.3.4. Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
15. Middle East Oncology Drugs Market;
15.1.1. Middle East Oncology Drugs Market Overview; 15.1.2. Middle East Oncology Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Oncology Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);
16. Africa Oncology Drugs Market;
16.1.1. Africa Oncology Drugs Market Overview; 16.1.2. Africa Oncology Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Oncology Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);
17. Oncology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. F. Hoffmann-La Roche Ltd; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Novartis Ag; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Celgene; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Johnson & Johnson; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Bristol-Myers Squibb Company 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Oncology Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
2. Oncology Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Oncology Drugs Market Customer Information;
5. Oncology Drugs Market Segmentation;
5.1. Global Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 5.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Oncology Drugs Market Trends And Strategies;
6. Oncology Drugs Market Regional And Country Analysis;
6.1. Global Oncology Drugs Market, 2016, By Region; 6.2. Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Oncology Drugs Market, 2016, By Country; 6.4. Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Oncology Drugs Market Comparison With Macro Economic Factors;
7.1. Oncology Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Oncology Drugs Expenditure, Global;
8. Oncology Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Oncology Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Oncology Drugs Expenditure, By Country;
9. Oncology Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Cancer, 2016, By Country;
10. Asia-Pacific Oncology Drugs Market;
10.1.1. Asia-Pacific Oncology Drugs Market Overview; 10.1.2. Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.2. Asia-Pacific Oncology Drugs Market: Country Analysis; 10.3. China Oncology Drugs Market; 10.3.1. China Oncology Drugs Market Overview; 10.3.2. China Oncology Drugs Historic Market, 2012 - 2016; 10.3.3. China Oncology Drugs Forecast Market, 2016 - 2020; 10.3.4. China Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.3.5. China Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.4. India Oncology Drugs Market; 10.4.1. India Oncology Drugs Market Overview; 10.4.2. India Oncology Drugs Historic Market, 2012 - 2016; 10.4.3. India Oncology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.4.5. India Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.5. Japan Oncology Drugs Market; 10.5.1. Japan Oncology Drugs Market Overview; 10.5.2. Japan Oncology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Oncology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.6. Australia Oncology Drugs Market; 10.6.1. Australia Oncology Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Oncology Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.6.4. Australia Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
11. Western Europe Oncology Drugs Market;
11.1.1. Western Europe Oncology Drugs Market Overview; 11.1.2. Western Europe Oncology Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Oncology Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.2. Western Europe Oncology Drugs Market: Country Analysis; 11.3. UK Oncology Drugs Market; 11.3.1. UK Oncology Drugs Market Overview; 11.3.2. UK Oncology Drugs Historic Market, 2012 - 2016; 11.3.3. UK Oncology Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.3.5. UK Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.4. Germany Oncology Drugs Market; 11.4.1. Germany Oncology Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Oncology Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.5 France Oncology Drugs Market; 11.5.1 France Oncology Drugs Historic Market, 2012 - 2016; 11.5.2 France Oncology Drugs Forecast Market, 2016 - 2020; 11.5.3 France Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.5.4 France Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.6. Italy Oncology Drugs Market; 11.6.2. Italy Oncology Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.6.4. Italy Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.7. Spain Oncology Drugs Market; 11.7.1. Spain Oncology Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Oncology Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.7.4. Spain Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Oncology Drugs Market;
12.1.1. Eastern Europe Oncology Drugs Market Overview; 12.1.2. Eastern Europe Oncology Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Oncology Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.2. Eastern Europe Oncology Drugs Market: Country Analysis; 12.3. Russia Oncology Drugs Market; 12.3.1. Russia Oncology Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Oncology Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 12.3.4. Russia Oncology Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
13. North America Oncology Drugs Market;
13.1.1. North America Oncology Drugs Market Overview; 13.1.2. North America Oncology Drugs Historic Market, 2012 - 2016; 13.1.3. North America Oncology Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.2. North America Oncology Drugs Market: Country Analysis; 13.3. USA Oncology Drugs Market; 13.3.1. USA Oncology Drugs Historic Market, 2012 - 2016; 13.3.2. USA Oncology Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 13.3.4. USA Oncology Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
14. South America Oncology Drugs Market;
14.1.1. South America Oncology Drugs Market Overview; 14.1.2. South America Oncology Drugs Historic Market, 2012 - 2016; 14.1.3. South America Oncology Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.2. South America Oncology Drugs Market: Country Analysis; 14.3. Brazil Oncology Drugs Market; 14.3.1. Brazil Oncology Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Oncology Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 14.3.4. Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;
15. Middle East Oncology Drugs Market;
15.1.1. Middle East Oncology Drugs Market Overview; 15.1.2. Middle East Oncology Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Oncology Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);
16. Africa Oncology Drugs Market;
16.1.1. Africa Oncology Drugs Market Overview; 16.1.2. Africa Oncology Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Oncology Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, Aids-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma);
17. Oncology Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. F. Hoffmann-La Roche Ltd; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Novartis Ag; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Celgene; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Johnson & Johnson; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Bristol-Myers Squibb Company 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Oncology Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
